Today announced that it has entered into settlement agreements with Takeda Pharmaceutical Co.

Product sales of $3.4 billion, according to IMS Health. Extra details of both agreements stay confidential and remain subject to review by the U.S. Division of Justice and the Government Trade Commission. Currently, Mylan has 142 ANDAs pending U.S. Food and Drug Administration acceptance representing $93.8 billion in annual brand sales; 40 of the pending ANDAs are potential first-to-file opportunities, representing $20 billion in annual brand product sales for the 12 weeks ending Dec. 31, 2010, according to IMS Health. SOURCE Mylan Inc.. Actoplus Met and Actos: Mylan enters into settlement agreements with Takeda Pharmaceutical Mylan Inc. today announced that it has entered into settlement agreements with Takeda Pharmaceutical Co.PRESS RELEASE Washington, D.C. – The American Pharmacists Association Basis’s proven diabetes administration solution, the individual Self-Management Credential for Diabetes, was highlighted Monday, May 18 at the Healthcare Leadership Council’s wellness briefing entitled, Controlling Diabetes: Innovations in Therapies and Treatment. HLC can be a coalition of chief executives of the country’s leading healthcare organizations and companies and advocates consumer-centered healthcare reform. Sanofi US, a member of HLC, invited APhA CEO Thomas Menighan to share information regarding the PSMC and the pharmacist’s role in diabetes care.